Rosen Comments on FDA Commissioner’s Tenure

09 March 2019 Modern Healthcare News
Partner David Rosen was quoted in a Modern Healthcare article, “Stakeholders anxious about FDA losing momentum after Gottlieb exits,” about the legacy of Food and Drug Administration Commissioner Dr. Scott Gottlieb, who announced his resignation last week.

Rosen said Gottlieb did a great job improving the generic-drug review and approval process, but that more needs to be done to address branded drugs that have no competition. “I still think the barrier to entry for generics is pretty high,” he said, citing the often insurmountable costs. “Also, the whole issue about patent certification is still subject to a fair amount of debate and clarification.”

Related Services

Insights

Text Messages, EDiscovery, and the New Threat to Privacy
21 November 2019
CMS Proposes Enhanced Scrutiny over Medicaid Supplemental Payments
20 November 2019
Health Care Law Today
The Purpose of a Corporation
November 2019
Legal News: Business Law
Should This Be a "Mobility" Industry Blog?
19 November 2019
Dashboard Insights
PATH Summit 2019
18-20 December 2019
Arlington, VA
Madison CLE Days
18-19 December 2019
Madison, WI
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
HFMA MA-RI Annual Compliance Update
12 December 2019
Boston, MA